공시 • Apr 02
Nascent Biotech, Inc. Files Form 15 Nascent Biotech, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. 공시 • Nov 16
Nascent Biotech, Inc. announced delayed 10-Q filing On 11/15/2024, Nascent Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. 공시 • Apr 17
Nascent Biotech, Inc. Prepares for Pivotal Phase II Research with Fresh Manufacturing Run Nascent Biotech, Inc. announced that it is embarking on a fresh manufacturing run to ensure Pritumumab ("PTB") supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial. This announcement comes as the Company prepares for a Phase II trial that follows a very successful Phase I trial-where safety at five ascending dose cohorts was observed-involving 15 patients who received PTB for various types of brain tumors. The most common and most challenging to treat tumor type in the trial was Gllioblastoma. 12 of 15 patients had this diagnosis. There were no dose-related toxicities. Overall, the study found that single agent Pritumumab is safe up to a dose of 16.2 mg/kg every 7 days in brain tumor patients. One partial response showed a 98.0% and 40.8% reduction in 2 tumor lesions for 21 months on study. Management anticipates that some research sites will open for the start of Phase II testing late this summer with actual patients involved later in 2024. 공시 • Mar 15
Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million. Nascent Biotech, Inc. has filed a Follow-on Equity Offering in the amount of $2.4 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 20,000,000
Price\Range: $0.12
Discount Per Security: $0 공시 • Aug 23
Nascent Biotech to Begin Phase II Clinical Trials for Brain Cancer Nascent Biotech, Inc. announced that the Company has been cleared by the FDA to begin Phase II clinical trials for brain cancer. This milestone allows the Company to continue advancing Pritumumab through the regulatory clinical processes in its use against Brain Tumors including Glioblastoma. Nascent Biotech therapeutic antibody Pritumumab (PTB) is a natural human antibody originally isolated from lymph nodes of a patient with cervical cancer. This monoclonal antibody targets cell surface Vimentin (also referred to as ectodomain vimentin), shown to be expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy that binds to the tumor and recruits the immune system to eliminate cancer cells. 공시 • Jan 26
Nascent Biotech, Inc. Completes Dosing Requirement in Final Cohort of Phase I Clinical Trial Nascent Biotech, Inc. announced the completion of the dosing period of their Phase I Clinical Trial evaluating the safety and dose tolerance of Pritumumab ("PTB") as a treatment for Brain Cancer. The completion of dosing for the fifth and final Phase I cohort completes safety and dose escalation. The Company will now prepare to submit data and the Phase II Clinical Protocol to the United States Food and Drug Administration (the "FDA") for evaluation. As the trial remains open for all active and follow-up participants enrolled, we look forward to providing more data on the safety and tolerability of Pritumumab. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells. 공시 • Jan 11
Nascent Biotech, Inc. Enrolls Final Patient Cohort in Phase I Brain Cancer Trial Nascent Biotech, Inc. announced the completion and closure of enrollment for the final cohort of patients involved in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer. Following the completion of patient dosing in this fifth and final cohort, the Company's Phase I trial will be complete. The Company will then prepare and submit research data to the FDA in preparation for the launch of its Phase 2 clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy which seeks out only cancer cells while sparing healthy cells. 공시 • Dec 21
Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board Nascent Biotech, Inc. announced that Dr. Ivan Babic, a renowned cancer expert, has been appointed to the Company's scientific advisory board. Dr. Babic is currently the Director of Gilman Biosciences. With more than 14 years' experience in translational oncology, he has been actively involved in drug discovery and development for the last 8 years. Dr. Babic has held positions at UCLA and UCSD's Moores Cancer Center. He was also Assistant Professor at the John Wayne Cancer Institute where his lab focused on identifying novel therapeutics for glioblastoma. 공시 • Oct 06
Nascent Biotech, Inc. Begins Enrollment of Final Patient Cohort to Complete Phase One Clinical Research Nascent Biotech, Inc. announced that the Company has enrolled the first patient of the fifth and final cohort of its Phase I clinical trial to evaluate Pritumumab (PTB) as a treatment for Primary and Metastatic Brain Cancers. Patient enrollment continues for Phase I and interested parties may review trial requirements at www.clinicaltrials.gov under the search term Pritumumab. Following completion of dosing of the Fifth Cohort, the Company will prepare data for submission to the FDA in preparation for Phase II clinical research. PTB is a natural human antibody that binds to Cell surface Vimentin (also referred to as ectodomain vimentin), a protein expressed on the surface of epithelial cancers. PTB is used as a targeted immunotherapy and seek out only cancer cells without damaging healthy cells. 공시 • Sep 14
Nascent Biotech, Inc. Completes Fourth Cohort in Phase 1 Human Trial for Primary and Metastatic Brain Cancer Nascent Biotech, Inc. announced the completion of the Fourth Cohort in dosing patients in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain Cancer, including Primary and metastatic Brain Tumors. After reviewing data gathered from the four completed cohorts, this milestone will allow the trial to advance to a fifth and final cohort. Patient enrollment continues for Phase I. Following completion of dosing of the Fifth Cohort, the Phase I trial will be complete, and the Company will prepare data for submission to the FDA in preparation for Phase 2 clinical research. 공시 • Jun 30
Nascent Biotech, Inc. announced delayed annual 10-K filing On 06/29/2021, Nascent Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. 공시 • Sep 24
Brandon Price Resigns as Executive Vice President and Director of Nascent Biotech, Inc, Effective September 30, 2020 On September 18, 2020, Brandon Price resigned as Executive Vice President and director of Nascent Biotech Inc. submitted his resignation. Mr. Price resigned for personal reasons due to life priorities and use of time. The company has agreed to accept his resignation effective as of September 30, 2020. 공시 • Aug 25
Nascent Biotech, Inc. announced that it has received $0.74 million in funding Nascent Biotech, Inc. (OTCPK:NBIO) announced that it has received $740,000 in equity funding on August 24, 2020. The transaction included participation from individual investors. 